Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q1 2024 · 10-Q
Revenue$37.93M$37.93M+10.3% vs Q1 2023 Net Income-$1.30M-$1.30MN/M vs Q1 2023 EPS Diluted$0.00$0.00— vs Q1 2023 Gross Profit$16,472,000+7.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Operating Cash Flow$3,210,000N/M Free Cash Flowderived-$158,000N/M Margins · derivedGross margin43.4%−1.3 pt vs Q1 2023
Operating margin5.3%−9.6 pt vs Q1 2023
Net margin-3.4%−1.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end